This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C15 / Special Copayment Reduction: V193 / 5% copayment (for 5 years from the cancer registration date) |
| B. Synonyms | Esophageal cancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma, Esophageal carcinoma, Esophageal cancer (EC) |
| C. Adult onset | Very high — mainly in the 60s (39.4% in Korea), followed by the 70s; about 7 times more common in men than in women |
| 1. History | History of esophageal cancer, development of esophageal surgery (Ivor Lewis), discovery of Barrett esophagus, the HER2 and immunotherapy era |
| 2. Causes | Smoking, alcohol (ESCC), GERD/obesity/Barrett esophagus (EAC), hot beverages, nitrosamines, achalasia |
| 3. Genetics | ESCC: TP53, CDKN2A, NFE2L2, NOTCH1; EAC: TP53, SMAD4, CDKN2A, HER2 amplification |
| 4. General epidemiology | About 3,100 cases per year in Korea, male-to-female ratio 6.9:1, ESCC 91.5%; high incidence in China and East Asia |
| 5. Pathophysiology | Field cancerization (ESCC), GERD → Barrett → dysplasia → adenocarcinoma (EAC), multistep carcinogenesis |
| 6. Symptoms | Dysphagia (progressive), weight loss, chest pain, regurgitation, nausea, hoarseness, melena |
| 7. Signs | Weight loss, cervical lymphadenopathy, vocal cord paralysis, esophagoscopic tumor findings, abnormal blood tests |
| 8. Screening | Endoscopy (Lugol staining/NBI), surveillance endoscopy for Barrett esophagus, early screening of high-risk groups |
| 9. Diagnosis | Upper gastrointestinal endoscopy + biopsy, CT, PET-CT, EUS, TNM (AJCC 8th edition), HER2 testing |
| 10. Treatment | Esophagectomy, CCRT, neoadjuvant chemoradiotherapy, trastuzumab, KEYNOTE-590/811, nivolumab |
| 11. Prognosis | 5-year survival: stage I 80%↑, stage II 40–50%, stage III 15–25%, stage IV less than 5% |
| 12. Prevention | Smoking cessation, moderation of alcohol intake, GERD treatment, obesity management, avoiding hot beverages, Barrett esophagus surveillance |
| 13. References | van Hagen P et al. N Engl J Med 2012 and 9 other papers |
Esophageal cancer is one of the oldest cancers in human history, and diseases involving dysphagia are described even in ancient Chinese medical texts. Systematic description of esophageal cancer in modern medicine began in the 19th century, and Czerny's attempt at the first esophagectomy in 1877 is the historical starting point of esophageal surgery. However, early surgical mortality was very high. In 1913, Franz Torek performed the first successful transthoracic esophagectomy, and in 1946 Ivor Lewis established esophagogastric anastomosis combining a right thoracotomy and abdominal approach (Ivor Lewis esophagectomy), which became the basis of the current standard procedure.
With the introduction of radiotherapy and chemotherapy in the 1950s–60s, the possibility of nonsurgical treatment of esophageal cancer began to be explored. In the 1980s, CCRT combining cisplatin-based chemotherapy with radiotherapy was shown to be effective in unresectable esophageal cancer. Barrett esophagus, described by Norman Barrett in 1950, is a state of intestinal metaplasia of the esophageal mucosa; it was later established as a chronic complication of gastroesophageal reflux and a precancerous lesion of esophageal adenocarcinoma.
In Korea, according to National Cancer Center data, more than about 3,000 cases of esophageal cancer occur per year, with squamous cell carcinoma overwhelmingly predominant at 91.5%. From the 2010s, HER2-targeted therapy (trastuzumab) was introduced for HER2-positive gastric and esophageal adenocarcinoma, and in the 2020s, as immune checkpoint inhibitor combination regimens such as KEYNOTE-590 (pembrolizumab + chemotherapy) and CheckMate-648 (nivolumab + chemotherapy) became established as first-line treatment for advanced esophageal cancer, the treatment paradigm was transformed.
The causes of esophageal cancer are clearly distinguished by histologic subtype. Esophageal squamous cell carcinoma (ESCC) accounts for the overwhelming majority in East Asia including Korea, and its main risk factors are smoking and alcohol. Smoking causes DNA damage through direct exposure of the esophageal mucosa to carcinogens in tobacco smoke. Alcohol damages the esophageal squamous epithelium through the mucosal toxicity of alcohol and acetaldehyde, and particularly in drinkers with the ALDH2-deficient genotype (observed in about 30–40% of East Asians), acetaldehyde accumulation increases, markedly raising the risk of ESCC.
Among dietary factors, drinking hot beverages of 65°C or higher (hot tea, hot porridge) has been classified by IARC as a Group 2A carcinogen and is associated with the high incidence of ESCC in parts of Central Asia, East Asia, and South America. Nitrosamine-containing foods (pickled vegetables, smoked meat), aflatoxin-contaminated foods, and diets low in vegetables and fruits are also implicated. The main risk factors for esophageal adenocarcinoma (EAC) are gastroesophageal reflux disease (GERD) and obesity. Repeated exposure of the esophageal mucosa to gastric acid and bile due to chronic GERD leads to Barrett esophagus, which progresses through dysplasia to adenocarcinoma. Obesity raises EAC risk by increasing abdominal pressure and promoting GERD.
In addition, achalasia increases the long-term risk of ESCC through food stasis and repeated irritation within the esophagus. Pharyngoesophageal diverticulum (Zenker's diverticulum) and the like are also rarely implicated. A history of radiotherapy (secondary esophageal cancer can arise after neck or mediastinal radiotherapy) is also a risk factor.
The molecular genetic characteristics of esophageal cancer are clearly divided between ESCC and EAC. In whole-genome analyses of ESCC, the most common somatic alteration is TP53 (about 80–90%), followed by CDKN2A deletion (50–60%), NFE2L2 (regulation of the oxidative stress response, 10–15%), NOTCH1 (10–20%), RB1 (5–15%), and FBXW7 (10%). EGFR amplification and CCND1 amplification are also observed in some ESCC. The smoking-related mutational signature (SBS4) is commonly identified in ESCC.
In EAC, the main genetic abnormalities are TP53 (about 70%), SMAD4 (about 10%), CDKN2A (about 15%), ARID1A (about 10%), PIK3CA (about 10%), and ERBB2 (HER2) amplification (about 15–20%). HER2 amplification is a particularly important therapeutic target in EAC and provides the rationale for chemotherapy combined with trastuzumab. VEGFR2 overexpression provides the rationale for ramucirumab targeted therapy. PD-L1 expression is observed in both ESCC and EAC and is used as a biomarker of response to immune checkpoint inhibitor therapy.
Progression from Barrett esophagus to EAC is explained by the accumulation of multistep genetic alterations. TP53 variants already occur at the stage of Barrett dysplasia, followed by CDKN2A deletion and increasing chromosomal aneuploidy, and finally amplification of growth factor receptors such as HER2 and VEGFR2 appears at the stage of invasive adenocarcinoma. Pharmacogenomically, polymorphisms of nucleotide excision repair genes such as ERCC1 and ERCC2 are associated with cisplatin sensitivity.
Esophageal cancer is diagnosed in about 600,000 people worldwide each year and is one of the leading causes of cancer-related death. ESCC is highly prevalent in East Asia (China, Korea, Japan, Iran, Central Asia), and in high-risk esophageal cancer areas (belt) such as Henan and Shanxi provinces in China, incidence exceeds 100 per 100,000 population. EAC is increasing in Western countries (US, UK, Australia), reflecting the rising prevalence of obesity and GERD.
Esophageal cancer incidence in Korea (per the Korea Central Cancer Registry, National Cancer Center): as of 2023, about 3,100 cases per year (1.1% of all cancers), with a crude incidence of 6.1 per 100,000 population. The male-to-female ratio is about 6.9:1, with men overwhelmingly predominant, and by age the 60s account for about 39.4%, the 70s 28.1%, and the 50s 15.0%. Histologically, ESCC accounts for 91.5% and adenocarcinoma 2.2%, making Korea an ESCC-dominant country. Incidence shows a gradual downward trend along with falling smoking rates, but the absolute number of cases is being maintained due to population aging.
In geographic distribution, the so-called 'esophageal cancer belt' including Henan Province, China, extends through Iran and Central Asia to East Africa. In these regions, hot beverages, nitrosamine-containing foods, and nutritional deficiencies commonly act as combined risk factors. In Korea, the distribution of drinking-related ALDH2 variant genotypes appears to contribute to the occurrence of ESCC.
The pathogenesis of esophageal cancer is divided into two main pathways. Pathogenesis of ESCC: the esophageal squamous mucosa is chronically damaged by carcinogens such as smoking and alcohol, and according to the concept of 'field cancerization,' genetic alterations accumulate at multiple sites throughout the esophagus or the upper digestive tract mucosa. TP53 variants occur early, CDKN2A deletion causes escape from the cell cycle, and NFE2L2 variants strengthen defenses against oxidative stress, helping carcinogenic cells survive. The multistep progression of dysplasia → carcinoma in situ (CIS) → invasive squamous cell carcinoma can be observed with Lugol's iodine staining or NBI endoscopy.
Pathogenesis of EAC (Barrett esophagus pathway): when the squamous mucosa of the distal esophagus is repeatedly exposed to gastric acid and bile due to chronic GERD, the normal squamous epithelium is replaced by acid-resistant columnar epithelium (intestinal metaplasia, columnar metaplasia). This state is 'Barrett esophagus.' The annual rate of malignant transformation of Barrett esophagus is about 0.1–0.3%. It then progresses in the order of low-grade dysplasia → high-grade dysplasia → invasive adenocarcinoma, with TP53, CDKN2A, chromosomal aneuploidy, and HER2 amplification accumulating at each stage. Obesity-related insulin resistance, hormonal changes, and a chronic hypoxic environment also promote progression from Barrett esophagus to EAC.
In common, both pathways pass through the stages of immunosuppression within the tumor microenvironment, angiogenesis (VEGF), epithelial-mesenchymal transition (EMT), acquisition of invasiveness, and lymphatic and hematogenous metastasis. Because the esophagus has a rich submucosal lymphatic network, metastasis to cervical, mediastinal, and abdominal lymph nodes occurs early.
The most characteristic and common symptom of esophageal cancer is progressive dysphagia. It begins with a sensation of obstruction when swallowing solid food, and as it progresses, swallowing soft and liquid diets also becomes difficult, until eventually even saliva is hard to swallow. Characteristically, this progressive course develops over weeks to months. Dysphagia is accompanied by weight loss, with an average weight loss of 10–15% at diagnosis being common. Malnutrition also negatively affects the treatment prognosis.
Chest pain or chest discomfort results from tumor invasion of the esophageal wall and compression or invasion of surrounding structures (aorta, mediastinum). Persistent back or retrosternal pain suggests invasion of the aorta or spine. Regurgitation, vomiting, and nausea are caused by esophageal obstruction, and regurgitation of food and saliva can cause aspiration pneumonia. Hoarseness indicates recurrent laryngeal nerve involvement, occurring when mediastinal lymph node metastasis or a tumor of the upper esophagus compresses or invades the nerve. Cough indicates a tracheoesophageal fistula or aspiration pneumonia, and when cough occurs during meals, an esophagotracheal connection should be suspected. Bloody stools (melena or hematemesis) are caused by bleeding from the tumor surface or esophageal ulcers, and chronic bleeding may be accompanied by anemia.
Unfortunately, early esophageal cancer is often asymptomatic or causes very mild symptoms, so diagnosis is frequently late. By the time dysphagia begins, the esophageal lumen has likely already been narrowed by tumor by about 60% or more.
Physical examination findings in esophageal cancer vary with the degree of progression. Early on, there are often no specific physical findings. The most important signs are marked weight loss and findings of malnutrition. Malabsorption, dehydration due to inability to swallow, and loss of subcutaneous fat and muscle are observed. Cervical lymphadenopathy is common in ESCC originating in the upper or cervical esophagus, and supraclavicular fossa lymphadenopathy suggests distant metastasis (similar to Virchow's node). When hoarseness due to vocal cord paralysis is identified on auscultation or history-taking, recurrent laryngeal nerve involvement is strongly suspected.
Horner syndrome (miosis, ptosis, anhidrosis) suggests sympathetic nerve involvement. Hepatomegaly may appear with liver metastasis. Blood tests may show anemia (chronic bleeding, malnutrition), hypoalbuminemia (malnutrition), abnormal liver function (liver metastasis or malnutrition), and elevated LDH and ALP (bone or liver metastasis). Tumor markers such as CEA, SCC antigen, and CA19-9 have low specificity and are used as adjuncts for tracking treatment response rather than for diagnosis. HER2 status is confirmed on tissue biopsy by immunohistochemistry (IHC) or FISH, which directly affects treatment selection.
When an esophagotracheal fistula develops, cough, fever, and findings of pneumonia are observed. The site of esophagotracheal connection may be identified on bronchoscopy. This generally arises in advanced ESCC during CCRT or due to progression, and palliative management with a bronchial or esophageal stent is required.
In Korea there is no separate national cancer screening program for esophageal cancer, but it is recommended that the esophageal mucosa also be observed during national gastric cancer screening (age 40 or older, gastroscopy or upper GI series every 2 years). In high-risk regions such as Henan Province, China, large-scale screening using Lugol's iodine staining endoscopy has been effective in detecting early esophageal cancer. Lugol staining marks normal squamous mucosa brown and dysplastic or cancerous areas unstained, making lesions easy to find.
Surveillance endoscopy for Barrett esophagus is a key screening tool for preventing EAC. In patients with GERD persisting for more than 5 years, obesity, or men aged 50 or older, endoscopy is performed to check for Barrett esophagus, and when Barrett esophagus is confirmed, regular surveillance endoscopy is performed according to the degree of dysplasia (low-grade dysplasia: every 6–12 months; high-grade dysplasia: consider endoscopic treatment or immediate surgery). Advanced endoscopic techniques such as narrow-band imaging (NBI) and confocal laser endomicroscopy increase the detection rate of dysplasia.
In high-risk groups (smokers of 30 pack-years or more, drinkers with ALDH2 variants, heavy consumers of hot beverages), regular esophageal evaluation by upper gastrointestinal endoscopy is recommended. Liquid biopsy using plasma DNA methylation or ctDNA (circulating tumor DNA) is being explored for esophageal cancer screening, but further research is needed for clinical establishment.
Esophageal cancer is confirmed by upper gastrointestinal endoscopy (EGD) + biopsy. On endoscopy, erythematous, raised, ulcerative, or stenotic lesions of the esophageal mucosa are identified, and biopsies are taken from multiple sites. Combined Lugol's iodine staining or NBI helps define the extent of lesions with indistinct borders. Squamous cell carcinoma or adenocarcinoma is confirmed on histopathology, and HER2 testing (IHC, FISH), PD-L1 CPS, and MMR/MSI testing are added.
For staging, contrast-enhanced CT (chest, abdomen, neck), PET-CT, and endoscopic ultrasound (EUS) are used as standard. CT is used to evaluate lymph node and distant metastasis, while EUS is most accurate for evaluating the tumor's T stage (depth of invasion into the mucosa and muscle layer) and is especially useful for distinguishing T1–T3. PET-CT is central to detecting occult distant metastasis (M1). AJCC 8th edition TNM staging: Tis (carcinoma in situ) → T1a (lamina propria), T1b (submucosa), T2 (muscularis propria), T3 (adventitia), T4a (invasion of pleura, pericardium, diaphragm), T4b (invasion of aorta, vertebra, trachea). N0 (no lymph node metastasis), N1 (1–2), N2 (3–6), N3 (7 or more). M1 is distant metastasis. For ESCC of the upper esophagus, cervical lymph nodes are also classified as regional lymph nodes.
If a tracheoesophageal fistula is suspected, bronchoscopy is additionally performed. Preoperative restaging using thoracoscopy or laparoscopy may be performed selectively. In some cases, peritoneal metastasis is ruled out by diagnostic laparoscopy.
Treatment of esophageal cancer is determined by stage. Early esophageal cancer (T1a) can be cured by endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR). In surgical candidates with T1b or higher to stage III disease, neoadjuvant concurrent chemoradiotherapy (neoadjuvant CCRT) followed by esophagectomy is standard. The CROSS study (van Hagen et al., NEJM 2012) demonstrated that carboplatin + paclitaxel + radiation (41.4Gy) followed by esophagectomy markedly improved OS compared with surgery alone (5-year survival 47% vs. 34%). Surgical approaches include Ivor Lewis esophagectomy (right thoracotomy + abdominal approach), McKeown esophagectomy (right thoracotomy + abdominal + cervical anastomosis), and minimally invasive esophagectomy (MIE).
For unresectable locally advanced disease (T4b) or when the patient's condition precludes surgery, definitive CCRT is an option, combining cisplatin + 5-FU or paclitaxel + carboplatin with radiation (50–50.4Gy). For first-line treatment of recurrent/metastatic esophageal cancer, based on the KEYNOTE-590 study, pembrolizumab + cisplatin + 5-FU improved OS in ESCC with PD-L1 CPS≥10 and in all EAC and is now the standard first-line treatment. CheckMate-648 (nivolumab + chemotherapy) also demonstrated improved OS in PD-L1-expressing ESCC and was approved. In HER2-positive EAC, pembrolizumab + trastuzumab + chemotherapy is standard based on KEYNOTE-811. Ramucirumab (VEGFR2 monoclonal antibody) is approved as second-line treatment.
Palliative measures include esophageal stent placement (relief of dysphagia), endoscopic laser therapy, and palliative radiotherapy. Nutritional support (nasogastric tube, percutaneous endoscopic gastrostomy, total parenteral nutrition) is essential for maintaining nutritional status during treatment.
The prognosis of esophageal cancer is very poor, with an overall 5-year survival of only about 15–20%, because the disease is often already at an advanced stage at diagnosis. 5-year survival by stage is reported as about 60–80% for Tis–T1, about 40–50% for T2N0, about 25–40% for T3N0, about 15–25% for stage III (with lymph node metastasis), and about 3–5% for stage IV (distant metastasis). In early esophageal cancer (eligible for ESD), 5-year survival exceeds 90%. Among patients who undergo surgery after neoadjuvant CCRT, those who achieve a pathologic complete response (pCR) have a markedly better long-term prognosis.
Prognostic factors include stage (T, N, M), histologic differentiation, number of lymph node metastases, margin status (R0 vs. R1/R2), response to preoperative therapy (pCR), and HER2 and PD-L1 expression status. In HER2-positive EAC, survival improves after combination treatment with trastuzumab. In ESCC with PD-L1 CPS≥10, the OS benefit of adding pembrolizumab is large. Since the CROSS study, 5-year OS has improved to about 47% in patients receiving neoadjuvant CCRT + surgery, and the CheckMate-577 study (postoperative adjuvant nivolumab) showed that adjuvant nivolumab significantly improved DFS in patients with residual disease after surgery following neoadjuvant CCRT.
Recurrence appears mainly as locoregional (anastomosis, mediastinum) and distant (lung, liver, bone) metastasis, most often within 2 years after surgery. In long-term follow-up after treatment, assessment of lung function, swallowing function, weight maintenance, nutritional status, and quality of life is important.
The most effective prevention of esophageal cancer, for ESCC, is smoking cessation and moderation of alcohol intake. Stopping smoking and drinking lowers the risk of esophageal carcinogenesis stepwise, with a synergistic effect when both are stopped. In carriers of the ALDH2 variant (rs671) genotype, even small amounts of alcohol carry a risk of acetaldehyde accumulation, so moderation or abstinence is especially important. Avoiding hot beverages (drinking after cooling to 65°C or below) is an effective preventive measure, especially in high-risk regions of Central and East Asia. A diet rich in vegetables and fruits, adequate nutrition, and avoidance of contaminated foods (aflatoxin, nitrosamines) are ancillary preventive measures.
For preventing EAC, active treatment of GERD (proton pump inhibitors), weight management (preventing obesity), and avoidance of factors that worsen acid reflux (high-fat diet, alcohol, caffeine, smoking) are key. When Barrett esophagus is identified, development of invasive EAC can be prevented by detecting high-grade dysplasia or early cancer through regular surveillance endoscopy and performing endoscopic treatment (ESD, EMR, radiofrequency ablation: RFA). Observational studies suggest that aspirin and NSAIDs somewhat lower the risk of EAC in Barrett esophagus, but routine preventive use is not recommended. Expansion of endoscopic screening programs in high-risk groups is expected to contribute to improving the prognosis of esophageal cancer.